Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company, announced on Tuesday that it has completed patient enrolment for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 intended to treat type 2 diabetes (T2D), surpassing its target of 675 patients with 710 patients enrolled.

ORA-D-013-1 is the larger of the company's two Phase three studies being carried out under US Food and Drug Administration (FDA) approved protocols to treat T2D patients who have inadequate glycaemic control over a period of six to 12 months.

The study will reveal efficacy data for the product after all patients have completed the first six-month treatment period. Topline data is likely to be revealed in January 2023.